TargetSeq® Hema Tumor Fusion RNA Panel is designed for the detection of known and unknown fusion events related to hematological tumors at the RNA level. It includes 141 common fusion genes such as KMT2A, RARα, NUP98, etc. and can detect low abundance transcripts and fusion genes with high sensitivity and accuracy. It is applicable to various scenarios such as disease diagnosis, disease treatment, prognosis determination, and recurrence monitoring.
Technical Platform | TargetSeq® Hybridization Capture Sequencing |
Coverage Size | 626.0 kb |
Reference Database | RefSeq |
Reference Genome | GRCh37 (hg19) |
Coverage | 141 common blood tumor fusion genes |
Storage | -20℃±5℃ |
Sequence Platform | Illumina / MGI |
Recommend Sequencing Read Length | PE150 |
Recommend Sequencing Data Size | 3 Gb |
Sensitive and accurate—Designed for all transcripts in the target region, it enables targeted capture of the target region, achieving low-cost, high-depth, and high-sensitivity detection.
Efficient and uniform—Leveraging iGeneTech® TargetSeq® probe hybridization capture sequencing technology, the kit delivers excellent performance.
Flexible customization—Custom and semi-custom services (such as probe densification and adding target regions) can be provided according to customer needs to meet personalized requirements.
.png "血液肿瘤RNA融合检测(1).png")
Figure 1. Test of Capture Data Performance of gDNA Reference Standards. Capture and sequencing were performed on gDNA samples, and both the coverage and uniformity of capture showed excellent performance, indicating excellent quality of probe design and synthesis.
| Product Name | Panel Number | Set | Cat. No |
| TargetSeq® Hema Tumor Fusion RNA Panel | T2689V1 | 24 rxn | PH2008285 |
| 96 rxn | PH2008282 |
CN
